Trial · NCT00660179
Adverse events843
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 843
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | Placebo | 32 | 249 | |
| other | UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | ACT-064992 3 mg | 48 | 250 | |
| other | UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | ACT-064992 10 mg | 37 | 242 | |
| other | OEDEMA PERIPHERAL | General disorders | Placebo | 45 | 249 | |
| other | OEDEMA PERIPHERAL | General disorders | ACT-064992 3 mg | 40 | 250 | |
| other | OEDEMA PERIPHERAL | General disorders | ACT-064992 10 mg | 44 | 242 | |
| other | NASOPHARYNGITIS | Infections and infestations | Placebo | 26 | 249 | |
| other | NASOPHARYNGITIS | Infections and infestations | ACT-064992 3 mg | 37 | 250 | |
| other | NASOPHARYNGITIS | Infections and infestations | ACT-064992 10 mg | 34 | 242 | |
| other | HEADACHE | Nervous system disorders | Placebo | 22 | 249 | |
| other | HEADACHE | Nervous system disorders | ACT-064992 3 mg | 33 | 250 | |
| other | HEADACHE | Nervous system disorders | ACT-064992 10 mg | 32 | 242 | |
| other | PULMONARY ARTERIAL HYPERTENSION | Respiratory, thoracic and mediastinal disorders | Placebo | 33 | 249 | |
| other | PULMONARY ARTERIAL HYPERTENSION | Respiratory, thoracic and mediastinal disorders | ACT-064992 3 mg | 29 | 250 | |
| other | PULMONARY ARTERIAL HYPERTENSION | Respiratory, thoracic and mediastinal disorders | ACT-064992 10 mg | 27 | 242 | |
| other | DIZZINESS | Nervous system disorders | Placebo | 27 | 249 | |
| other | DIZZINESS | Nervous system disorders | ACT-064992 3 mg | 24 | 250 | |
| other | DIZZINESS | Nervous system disorders | ACT-064992 10 mg | 26 | 242 | |
| other | ANAEMIA | Blood and lymphatic system disorders | Placebo | 7 | 249 | |
| other | ANAEMIA | Blood and lymphatic system disorders | ACT-064992 3 mg | 18 | 250 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00660179/events